Is there a window of opportunity to optimize trastuzumab cardiac monitoring?

Table 1 Patients and treatment characteristics

Variable	Absolute number	Percentage
Age
Minimum	18	-
Median	52	-
Maximum	79	-
Body mass index
Minimum	14.27	-
Median	27.54	-
Maximum	50.58	-
Comorbidities
Hypertension	56	13.75
Diabetes	19	4.66
Lack of other comorbidities reported	330	81.10
Menopausal status
Post-menopausal	304	74.69
Pre-menopausal	103	25.31
Histological subtypes
Invasive ductal carcinoma	400	98.28
Invasive lobular carcinoma	5	1.22
Others	2	0.50
Clinical stage
I	36	8.86
II	129	31.69
III	242	59.45
Chemotherapy regimen
Anthracycline and taxane based	381	93.61
Non-anthracycline based	26	6.39
Chemotherapy purpose
Neoadjuvant	204	50.12
Adjuvant	203	48.88
Adjuvant radiotherapy
Yes	213	52.33
No	194	47.67
Trastuzumab duration
1 yr	395	97.06
Less than 1 yr	12	2.94